An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome.

An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome. Abstract Text:

BACKGROUND: Lenalidomide is an effective new agent for the treatment of patients with myelodysplastic syndrome (MDS), an acquired hematopoietic disorder characterized by ineffective blood cell production and a predisposition to the development of leukemia. Patients with an interstitial deletion of Chromosome 5q have a high rate of response to lenalidomide, but most MDS patients lack this deletion. Approximately 25% of patients without 5q deletions also benefit from lenalidomide therapy, but response in these patients cannot be predicted by any currently available diagnostic assays. The aim of this study was to develop a method to predict lenalidomide response in order to avoid unnecessary toxicity in patients unlikely to benefit from treatment. METHODS AND FINDINGS: Using gene expression profiling, we identified a molecular signature that predicts lenalidomide response. The signature was defined in a set of 16 pretreatment bone marrow aspirates from MDS patients without 5q deletions, and validated in an independent set of 26 samples. The response signature consisted of a cohesive set of erythroid-specific genes with decreased expression in responders, suggesting that a defect in erythroid differentiation underlies lenalidomide response. Consistent with this observation, treatment with lenalidomide promoted erythroid differentiation of primary hematopoietic progenitor cells grown in vitro. CONCLUSIONS: These studies indicate that lenalidomide-responsive patients have a defect in erythroid differentiation, and suggest a strategy for a clinical test to predict patients most likely to respond to the drug. The experiments further suggest that the efficacy of lenalidomide, whose mechanism of action in MDS is unknown, may be due to its ability to induce erythroid differentiation.

An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome. Publishing Authors By Initials

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: PLoS medicine

VOLUME: 5

Page Numbers: e35

Journal Abbreviation: PLoS Med.

ISSN: 1549-1676

DAY: 28

MONTH: Feb

YEAR: 2008

An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 101231360

An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome.

AFFILIATION:

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: PLoS Med

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome Related Publications

• 'I just thought it was normal aches and pains': a qualitative study of decision-making processes in patients with early rheumatoid arthritis.
• A child with acute appendicitis.
• An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome.
• Beliefs about medicines in patients with rheumatoid arthritis and systemic lupus erythematosus: a comparison between patients of South Asian and White British origin.
• Benign fibrous histiocytoma of the rib.
• Comment on: Delay in presentation to primary care physicians is the main reason why patients with rheumatoid arthritis are seen late by rheumatologists: reply.
• Comparison of two methods (precipitation manual and fully automated enzymatic) for the analysis of HDL and LDL cholesterol.
• Computer audiogram.
• Current treatment options: impact of cytogenetics on the course of myelodysplasia.
• Disorders of sex development (DSDs), their presentation and management in different cultures.
• Eosinophilia with FIP1L1-PDGFRA fusion in a patient with chronic myelomonocytic leukemia.
• Facilitating treatment of anxiety disorders in patients with comorbid medical illness.
• Immunomodulatory drugs in myelodysplastic syndromes.
• In situ end labelling of DNA to detect apoptotic cell death in a variety of human tumours.
• In vitro assessment of drug sensitivity in acute nonlymphocytic leukemia.
• Interferon alpha 2a in patients of chronic hepatitis C.
• Localized lesions in secondary syphilis.
• Myocardial revascularization.
• Power Doppler sonography of breast cancer: does vascularity correlate with node status or lymphatic vascular invasion?
• Re: Obtaining previous mammograms for comparison.
• Silent myocardial ischemia.
• Studies on flammability of clothing of burn victims, changes therein and their wearability after a borax rinse.
• Studies on flammability of clothing of burn victims, changes therein and their wearability after a borax rinse.
• The assessment of risk factors for postoperative nausea and vomiting.
• The efficacy of Silybum marianum (L.) Gaertn. (silymarin) in the treatment of type II diabetes: a randomized, double-blind, placebo-controlled, clinical trial.
• The role of family configuration in early childhood intellectual development in the context of an extended family system in Pakistan.
• Validation of a prediction rule for disease outcome in patients with recent-onset undifferentiated arthritis: Moving toward individualized treatment decision-making.